TABLE 4.
Relative agonist rank order of efficacy for IP accumulation, Ca2+ release, and ERK1/2 phosphorylation in WT and RSK2 KO MEFs
Letters in parentheses indicate group assignment. Mean relative efficacies were analyzed via one-way ANOVA, and significant differences were determined via the Tukey-Kramer multiple comparison post-test (significance set at p < 0.05). Agonists were arranged in descending order (i.e. 1 through 9) and placed into statistically homogeneous groups (i.e., a through f) such that significant differences in rank order are denoted by changes in group membership. Agonists with nonoverlapping group assignments were considered to be significantly different.
| Rank Order | IP Accumulation |
Ca2+ Release |
ERK1/2 Phosphorylation |
|||
|---|---|---|---|---|---|---|
| WT MEFs | RSK2 KO MEFs | WT MEFs | RSK2 KO MEFs | WT MEFs | RSK2 KO MEFs | |
| 1 | 5-HT (a) | 5-Methoxy DMT (a) | a-Me5-HT (a) | a-Me5-HT (a) | Quipazine (a) | DOI (a) |
| 2 | a-Me5-HT (a,b) | Quipazine (a) | 5-HT (a,b) | 5-HT (a) | m-CPP (a) | 5-Methoxy DMT (a) |
| 3 | Quipazine (b,c) | DOI (a,b) | Quipazine (a,b,c) | MK212 (a) | 5-HT (a) | a-Me5-HT (a,b) |
| 4 | MK212 (c) | 5-HT (a) | DOI (a,b,c) | Quipazine (a,b) | DOI (a,b) | 5-HT (a) |
| 5 | DOI (c,d) | MK212 (b,c) | 5-Methoxy DMT (b,c,d) | 5-Methoxy DMT (a,b,c) | Lisuride (a,b) | Lisuride (a,b) |
| 6 | 5-Methoxy DMT (d) | a-Me5-HT (c) | MK212 (c,d) | DOI (a,b,c) | 5-Methoxy DMT (a,b) | Quipazine (a,b) |
| 7 | m-CPP (e) | m-CPP (c,d) | m-CPP (d) | m-CPP (a,b,c) | a-Me5-HT (a,b,c) | MK212 (a,b) |
| 8 | Lisuride (e,f) | Lisuride (d) | Lisuride (e) | Lisuride (b,c) | MK212 (b,c) | m-CPP (a,b) |
| 9 | SCH-23390 (f) | SCH-23390 (d) | SCH-23390 (e) | SCH-23390 (c) | SCH-23390 (c) | SCH-23390 (b) |